Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: A meta-analysis of randomized trials

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 4, 2014, Pages 339-350

  Verdoia, Monica ^a   Schaffer, Alon ^a   Barbieri, Lucia ^a   Cassetti, Ettore ^a   Piccolo, Raffaele ^b   Galasso, Gennaro ^b   Marino, Paolo ^a   Sinigaglia, Fabiola ^a   De Luca, Giuseppe ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

cardiovascular outcome; clopidogrel; P2Y12 Receptor antagonists

Indexed keywords

ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONIST; CANGRELOR; CARDIAC AGENT; CLOPIDOGREL; PRASUGREL; TICAGRELOR; UNCLASSIFIED DRUG; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CARDIAC PATIENT; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; STABLE ANGINA PECTORIS; STENT; STENT THROMBOSIS; SYMPTOMATOLOGY; ANALOGS AND DERIVATIVES; ANGINA, STABLE; BIOASSAY; CASE MANAGEMENT; COMPARATIVE STUDY; FEMALE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE DIPHOSPHATE; ANGINA, STABLE; CASE MANAGEMENT; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84898596687     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000052     Document Type: Article

References (34)

1. Hamm CW, Bassand JP, Agewall S, et al; ESC Committee for Practice Guidelines. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999-3054
2. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Kolh P, Wijns W, Danchin N, et al. Guidelines on myocardial revascularization. Eur J Cardiothorac Surg. 2010;38 (suppl):S1-S52.
3. De Luca G, Smit JJ, Ernst N, et al. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost. 2005;93:820-823.
4. De Luca G, Cassetti E, Verdoia M, et al. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analysis of randomised trials. Thromb Haemost. 2009;102:428-436.
5. Navarese EP, Kubica J, Castriota F, et al. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention. 2011;7:985-994.
6. Di Lorenzo E, De Luca G, Sauro R, et al. The PASEO (PaclitAxel or Sirolimus-eluting stent versus bare metal stent in primary angioplasty) randomized trial. JACC Cardiovasc Interv. 2009;2:515-523.
7. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109: 3171-3175.
8. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913.
9. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidog-rel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29: 21-30.
10. Campo G, Fileti L, De Cesare N, et al; on behalf of the 3T/2R Investigators. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol. 2010;56:1447-1455.
11. De Luca G, Ernst N, van 't Hof AW, et al. Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J. 2006;151:1256-1259.
12. De Luca G, Suryapranata H, Stone GW, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol. 2008;126:37-44.
13. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65-W94.
14. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
15. Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagre-lor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
16. Cannon CP, Husted S, Harrington RA, et al; DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidog-rel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50: 1844-1851.
17. Erratum in: J Am Coll Cardiol. 2007;50:2196.
18. Roe MT, Armstrong PW, Fox KA, et al; TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297-1309.
19. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361:2318-2329.
20. Bhatt DL, Lincoff AM, Gibson CM, et al; CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361:2330-2341.
21. Bhatt DL, Stone GW, Mahaffey KW, et al; the CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303-1313.
22. Wiviott SD, Antman EM, Winters KJ, et al; JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005; 111:3366-3373.
23. Dangas GD, Claessen BE, Mehran R, et al. Stent thrombosis after primary angioplasty for STEMI in relation to non adherence to dual anti-platelet therapy over time: results of the HORIZONS-AMI trial. EuroIntervention. 2013;8:1033-1039.
24. De Luca G, Cassetti E, Marino P. Percutaneous coronary intervention-related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. Am J Emerg Med. 2009;27:712-719.
25. De Luca G, Dirksen MT, Spaulding C, et al. Drug-eluting versus bare-metal stents in primary angioplasty. A pooled patient-level meta-analysis of randomized trials. Arch Intern Med. 2012;172:611-621.
26. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
27. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol. 2003;91:1123-1125.
28. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003;89:783-787.
29. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505-1516.
30. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost. 2007;97:282-287
31. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930-942.
32. Serebruany VL, Atar D. The PLATO trial: do you believe in magic? Eur Heart J. 2010;31:764-767.
33. Thygesen K, Alpert JS, Jaffe AS, et al. Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocar-dial Infarction, Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551-2567.
34. Leonardi S, Truffa AA, Neely ML, et al. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart. 2013;99:1282-1287.